Literature DB >> 10461895

Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes.

S M Rawls1, J F McGinty, D M Terrian.   

Abstract

In addition to cytosolic efflux, reversal of excitatory amino acid (EAA) transporters evokes glutamate exocytosis from the striatum in vivo. Both kappa-opioid and muscarinic receptor agonists suppress this calcium-dependent response. These data led to the hypothesis that the calcium-independent efflux of striatal glutamate evoked by transporter reversal may activate a transsynaptic feedback loop that promotes glutamate exocytosis from thalamo- and/or corticostriatal terminals in vivo and that this activation is inhibited by presynaptic kappa and muscarinic receptors. Corollaries to this hypothesis are the predictions that agonists for these putative presynaptic receptors will selectively inhibit the calcium-dependent component of glutamate released from striatal synaptosomes, whereas the calcium-independent efflux evoked by an EAA transporter blocker, L-trans-pyrrolidine-2,4-dicarboxylic acid (L-trans-PDC), will be insensitive to such receptor ligands. Here we report that a muscarinic agonist, oxotremorine (0.01-10 microM), and a kappa-opioid agonist, U-69593 (0.1-100 microM), suppressed the calcium-dependent release of glutamate that was evoked by exposing striatal synaptosomes to the potassium channel blocker 4-aminopyridine. The presynaptic inhibition produced by these ligands was concentration dependent, blocked by appropriate receptor antagonists, and not mimicked by the delta-opioid agonist [D-Pen2,5]-enkephalin. The finding that glutamate efflux evoked by L-trans-PDC from isolated striatal nerve endings was entirely calcium independent supports the notion that intact basal ganglia circuitry mediates the calcium-dependent effects of this agent on glutamate efflux in vivo. Furthermore, because muscarinic or kappa-opioid receptor activation inhibits calcium-dependent striatal glutamate release in vitro as it does in vivo, it is likely that both muscarinic and kappa receptors are inhibitory presynaptic heteroceptors expressed by striatal glutamatergic terminals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461895     DOI: 10.1046/j.1471-4159.1999.0731058.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Idebenone inhibition of glutamate release from rat cerebral cortex nerve endings by suppression of voltage-dependent calcium influx and protein kinase A.

Authors:  Yi Chang; Yu-Wan Lin; Su-Jane Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

3.  Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum.

Authors:  Jennifer L Werkheiser; Scott M Rawls; Alan Cowan
Journal:  Neuropharmacology       Date:  2006-12-05       Impact factor: 5.250

4.  Kappa Opioid Receptors Mediate Heterosynaptic Suppression of Hippocampal Inputs in the Rat Ventral Striatum.

Authors:  Julie M Brooks; Patricio O'Donnell
Journal:  J Neurosci       Date:  2017-06-22       Impact factor: 6.167

Review 5.  Optogenetic studies of nicotinic contributions to cholinergic signaling in the central nervous system.

Authors:  Li Jiang; Gretchen Y López-Hernández; James Lederman; David A Talmage; Lorna W Role
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

6.  Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Kristin N Schultz-Kuszak; Omar S Mabrouk; Robert T Kennedy; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

Review 7.  Dynorphin and the pathophysiology of drug addiction.

Authors:  T S Shippenberg; A Zapata; V I Chefer
Journal:  Pharmacol Ther       Date:  2007-07-24       Impact factor: 12.310

8.  Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system.

Authors:  Sunil Sirohi; Georgy Bakalkin; Brendan M Walker
Journal:  Front Mol Neurosci       Date:  2012-09-27       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.